Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004782-39
    Sponsor's Protocol Code Number:DS8201-A-U207
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-09-01
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-004782-39
    A.3Full title of the trial
    A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
    Estudio en fase II, multicéntrico y aleatorizado de trastuzumab deruxtecán en sujetos con cáncer colorrectal localmente avanzado, irresecable o metastásico con sobreexpresión de HER2 (DESTINY-CRC02)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Trastuzumab deruxtecan for subjects with HER2-overexpressing advanced or metastatic CRC
    Trastuzumab deruxtecán para sujetos con CCR avanzado o metastásico con sobreexpresión de HER2
    A.3.2Name or abbreviated title of the trial where available
    DESTINY-CRC02
    A.4.1Sponsor's protocol code numberDS8201-A-U207
    A.5.4Other Identifiers
    Name:IND numberNumber:136179
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDaiichi Sankyo Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDaiichi Sankyo Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDaiichi Sankyo Inc.
    B.5.2Functional name of contact pointDavid Rusnak
    B.5.3 Address:
    B.5.3.1Street Address211 Mount Airy Road
    B.5.3.2Town/ cityBasking Ridge
    B.5.3.3Post codeNJ 07920
    B.5.3.4CountryUnited States
    B.5.4Telephone number1908992 7876
    B.5.6E-maildrusnak@dsi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTrastuzumab deruxtecan
    D.3.2Product code T-DXd, DS-8201a
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTrastuzumab deruxtecan
    D.3.9.1CAS number 1826843-81-5
    D.3.9.2Current sponsor codeDS-8201a
    D.3.9.3Other descriptive nameAnti-HER2 antibody-drug conjugate
    D.3.9.4EV Substance CodeSUB188357
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer
    Cáncer colorrectal localmente avanzado, irresecable o metastásico con sobreexpresión de HER2
    E.1.1.1Medical condition in easily understood language
    Colorectal Cancer
    Cáncer colorrectal
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10061451
    E.1.2Term Colorectal cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of T-DXd, as measured by the confirmed ORR by BICR in HER2-overexpressing (defined as IHC 3+ or IHC 2+/ISH+) mCRC subjects treated at the 5.4 mg/kg and 6.4 mg/kg doses
    Evaluar la eficacia de trastuzumab deruxtecán (T-DXd), medida mediante la TRO confirmada mediante RCIE en sujetos con CCRm con sobreexpresión de HER2 (definidos como IHQ 3+ o IHQ 2+/HIS+) tratados con las dosis de 5,4 mg/kg y 6,4 mg/kg
    E.2.2Secondary objectives of the trial
    • To evaluate the clinical efficacy of T-DXd by confirmed ORR by Investigator assessment;
    • To evaluate the clinical efficacy of T-DXd by DoR;
    • To further evaluate the clinical efficacy of T-DXd by DCR, CBR, PFS and OS;
    • To further evaluate the safety and tolerability of T-DXd;
    • To evaluate HEOR endpoints including patient-reported HRQoL, symptoms, and physical functioning;
    • To evaluate healthcare resource utilization for both treatment arms;
    • To evaluate PK of T-DXd;
    • To evaluate immunogenicity of T-DXd.
    • Evaluar la eficacia clínica de la T-DXd mediante la TRO confirmada según la evaluación del investigador;
    • Evaluar la eficacia clínica de T-DXd mediante la DR;
    •Seguir evaluando la eficacia clínica de T-DXd por TCE, TBC, SSP y SG;
    •Seguir evaluando la seguridad y la tolerabilidad de T-DXd;
    •Evaluar los criterios de valoración HEOR, incluidos la CdVRS notificada por el paciente, los síntomas y la función física;
    •Evaluar la utilización de recursos sanitarios para ambos grupos de tratamiento;
    •Evaluar la FC de T-DXd
    •Evaluar la inmunogenicidad de T-DXd
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Sign and date the Tissue Pre-Screening and Main ICFs, prior to the start of any respective study-specific qualification procedures.
    2. Adults aged ≥20 years in Japan, Taiwan, and Korea, or those aged ≥ 18 years in other countries, at the time the ICFs are signed. (Please follow local regulatory requirements if the legal age of consent for study participation is >18 years).
    3. Pathologically-documented, unresectable, recurrent, or metastatic colorectal adenocarcinoma. Subject must have BRAF wild-type cancer and RAS status identified in primary or metastatic site, tested by a Clinical Laboratory Improvement Act (CLIA), ISO15189, or equivalent-certified laboratory.
    4. The following therapies should be included in prior lines of therapy:
    a. Fluoropyrimidine, oxaliplatin, and irinotecan, unless contraindicated
    b. Anti-EGFR treatment, if RAS wild-type and if clinically indicated
    c. Anti-VEGF treatment, if clinically indicated
    d. Anti-PD-(L)-1 therapy, if tumor is MSI-high/deficient mismatch repair (dMMR), or tumor mutational burden (TMB)-high, if clinically indicated
    5. Is willing and able to provide an adequate tumor sample for tissue pre-screening to confirm HER2 status by central laboratory (most recent tumor tissue preferred).
    6. Confirmed HER2-overexpressing status assessed by central laboratory and defined as IHC 3+ or IHC 2+/ISH+.
    7. Presence of at least one measurable lesion assessed by the Investigator per RECIST version 1.1. Lesions situated in a previously-irradiated area are considered measurable if progression has been demonstrated in such lesions after the end of radiotherapy.
    8. ECOG PS of 0 or 1.
    9. Has LVEF ≥50% within 28 days before randomization/registration.
    10. Has adequate organ function within 14 days before randomization/registration as defined in the protocol.
    11. Has adequate treatment washout period before randomization/registration as defined in the protocol.
    12. If the subject is a woman of childbearing potential, she must have a negative urine pregnancy test within 72 hours before randomization/registration; a positive urine pregnancy test result must immediately be confirmed using a serum test. The subject must also be willing to use highly effective birth control, as detailed in Section 10.3.4, upon randomization/registration, during the Treatment Period, and for 7 months, following the last dose of study drug. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently sterile (undergone a hysterectomy, bilateral
    salpingectomy, or bilateral oophorectomy).
    a. Non-childbearing potential is defined as premenopausal female subjects with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] >40 mIU/mL and estradiol <40 pg/mL [<147 pmol/L] is confirmatory). Female subjects on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of childbearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to randomization/registration. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their postmenopausal status, they can resume use of HRT during the study without use of a contraceptive method.
    13. If male, the subject must be surgically sterile or willing to use highly effective birth control (Section 10.3.4) upon randomization/registration, during the Treatment Period, and for 4 months following the last dose of study drug.
    14. Male subjects must not freeze or donate sperm starting at Screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to randomization/registration in this study.
    15. Female subjects must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study Treatment Period, and for at least 7 months after the final study drug administration.
    16. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
    17. Life expectancy is ≥3 months.
    1.Firmar y fechar los FCI de preselección de tejido y principal, antes del inicio de cualquier procedimiento de cualificación específico del estudio.
    2.Adultos de ≥20 años de edad en Japón, Taiwán y Corea, o personas ≥18 años en otros países, en el momento de firmar los FCI. (Siga las disposiciones reglamentarias locales si la edad legal de consentimiento para la participación en un estudio es >18 años de edad.)
    3.Adenocarcinoma colorrectal metastásico, irresecable, recurrente o documentado patológicamente. El sujeto debe tener cáncer con BRAF de tipo salvaje y estado de RAS identificado en el sitio primario o metastásico, analizado por una Ley de mejora de laboratorio clínico (Clinical Laboratory Improvement Act, CLIA), ISO15189 o laboratorio equivalente certificado.
    4.Se deben incluir los siguientes tratamientos en líneas de tratamiento previas:
    a. Fluoropirimidina, oxaliplatino e irinotecán, a menos que estén contraindicados
    b.Tratamiento contra el receptor del factor de crecimiento epidérmico (EGFR), si presenta RAS de tipo natural y si está clínicamente indicado
    c. Tratamiento con factor de crecimiento endotelial vascular (VEGF), si está clínicamente indicado
    d. Tratamiento con anti-ligando 1 de muerte programada (PD-[L]-1), si el tumor presenta una alta inestabilidad microsatelital (IMS)/reparación deficiente de los errores de emparejamiento (dMMR), o con alta carga mutacional tumoral (CMT), si está clínicamente indicado
    5.Está dispuesto y es capaz de proporcionar una muestra tumoral adecuada para la preselección de tejido para confirmar el estado HER2 por parte del laboratorio central (preferentemente el tejido tumoral más reciente).
    6.Estado de sobreexpresión de HER2 confirmado evaluado por el laboratorio central y definido como IHQ 3+ o IHQ 2+/HIS+.
    7.Presencia de al menos una lesión medible evaluada según la versión 1.1 de los Criterios de evaluación de la respuesta en tumores sólidos (RECIST) por el investigador. Las lesiones que se encuentren en una zona irradiada con anterioridad se consideran medibles en el caso de que se haya demostrado progresión en dichas lesiones después del final de la radioterapia.
    8.EF del ECOG de 0 o 1.
    9.Fracción de eyección del ventrículo izquierdo (FEVI) ≥50 % en los 28 días previos a la aleatorización/el registro.
    10.Tener función orgánica adecuada en los 14 días anteriores a la aleatorización/el registro según el protocol.
    11.Tiene un periodo de reposo farmacológico adecuado antes de la aleatorización/el registro según el protocolo.
    12.Si el sujeto es una mujer en edad fértil, debe tener un resultado negativo en la prueba de embarazo en orina en las 72 horas anteriores a la aleatorización/el registro; un resultado positivo en la prueba de embarazo en orina debe confirmarse inmediatamente mediante una prueba en suero. Además, debe estar dispuesta a utilizar un método anticonceptivo altamente eficaz, como se detalla en la sección 10.3.4, tras la aleatorización/el registro, durante el periodo de tratamiento, y durante 7 meses después de la última dosis del fármaco del estudio. Se considera que una mujer está en edad fértil después de la menarquia y hasta convertirse en posmenopáusica (sin periodo menstrual durante un mínimo de 12 meses) a menos que sea estéril de forma permanente (se haya sometido a una histerectomía, salpingectomía bilateral u ovariectomía bilateral).
    a. Se define como no en edad fértil a mujeres premenopáusicas con ligadura de trompas o histerectomía documentadas; o se define como posmenopáusicas a mujeres tras 12 meses de amenorrea espontánea (en casos cuestionables, una muestra de sangre con hormona foliculoestimulante [FSH] simultánea >40 mUI/ml y estradiol <40 pg/ml [<147 pmol/l] es confirmatoria). Las mujeres con tratamiento hormonal sustitutivo (THS) cuyo estado menopáusico sea dudoso tendrán que usar uno de los métodos anticonceptivos descritos para las mujeres en edad fértil si desean seguir con su THS durante el estudio. De lo contrario, deben interrumpir el THS para permitir la confirmación del estado posmenopáusico antes de la aleatorización/el registro. Con la mayoría de las formas de THS, transcurrirán al menos entre 2 y 4 semanas desde el cese del tratamiento hasta la extracción de sangre; este intervalo dependerá del tipo y la posología del THS. Tras la confirmación de su estado posmenopáusico, pueden reiniciar el THS durante el estudio sin tener que usar un método anticonceptivo.
    13. Si el sujeto es un hombre, debe ser quirúrgicamente estéril o estar dispuesto a utilizar un método anticonceptivo altamente eficaz (sección 10.3.4) tras la aleatorización/el registro, durante el periodo de tratamiento y durante 4 meses después de la última dosis del fármaco del estudio.
    Ver el protocol para más información.
    E.4Principal exclusion criteria
    1. Medical history of myocardial infarction (MI) within 6 months before randomization/registration, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Subjects with troponin levels above ULN at Screening (as defined by the manufacturer), and without any MI-related symptoms, should have a cardiologic consultation before randomization/registration to rule out MI.
    2. Has a corrected QT interval (QTcF) prolongation to >470 msec (female subjects) or >450 msec (male subjects) based on the average of the Screening triplicate 12-lead ECGs.
    3. Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
    4. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the randomization/registration, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.).
    5. Any autoimmune, connective tissue, or inflammatory disorders (eg, rheumatoid arthritis, Sjögren syndrome, sarcoidosis, etc.) where there is documented, or a suspicion of, pulmonary involvement at the time of Screening. Full details of the disorder should be recorded in the electronic case report form (eCRF) for subjects who are included in the study.
    6. Prior pneumonectomy.
    7. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and randomization/registration.
    8. Subjects with leptomeningeal carcinomatosis.
    9. Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated.
    10. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
    11. Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
    12. Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
    13. Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions that may in the opinion of the Investigator, interfere with the subject’s participation in the clinical study or evaluation of the clinical study results.
    14. Has known human immunodeficiency virus (HIV) infection. Unless required by local regulations or institutional review board (IRB)/ethics committee (EC), an HIV antigen/antibody test is not required prior to randomization/enrollment.
    15. Active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of viral infection within 28 days before study randomization/registration. Subjects with past or resolved hepatitis B virus (HBV) infection are eligible if hepatitis B surface antigen (HBsAg) negative (-) and antibody to hepatitis B core antigen (anti-HBc) positive (+). Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
    16. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, Grade ≤1 or baseline. Subjects with chronic Grade 2 toxicities may be eligible at the discretion of the Investigator and approval of the Sponsor.
    17. Previous treatment with a DXd-containing ADC.
    18. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Note: Subjects with localized fungal infections of skin or nails are eligible.
    19. Female subject who is pregnant, breastfeeding, or intends to become pregnant during the study.
    20. Psychological, social, familial, or geographical factors that would prevent regular follow-up.
    21. Otherwise considered inappropriate for the study by the Investigator.
    1.Antecedentes médicos de infarto de miocardio (IM) en los 6 meses anteriores a la aleatorización/al registro, insuficiencia cardíaca congestiva (ICC) sintomática (clase II a IV de la New York Heart Association). Los sujetos con niveles de troponina por encima del LSN en la selección (según la definición del fabricante) y sin síntomas relacionados con el IM deben someterse a una consulta cardiológica antes de la aleatorización/del registro para descartar el IM.
    2.Presentar una prolongación del intervalo QT corregido (QTcF) hasta >470 ms (mujeres) o >450 ms (hombres) basado en el promedio del electrocardiograma de 12 derivaciones por triplicado de la selección.
    3.Tener antecedentes de enfermedad pulmonar intersticial (EPI) (no infecciosa)/neumonitis que requiere corticoesteroides, EPI/neumonitis actual o sospecha de EPI/neumonitis que no puede descartarse mediante diagnóstico por imagen en la selección.
    4.Enfermedades clínicamente significativas intercurrentes específicas del pulmón, incluidas, entre otras, cualquier trastorno pulmonar subyacente (p. ej., embolias pulmonares en los 3 meses anteriores a la aleatorización/al registro, asma grave, enfermedad pulmonar obstructiva crónica [EPOC] grave, enfermedad pulmonar restrictiva, derrame pleural, etc.).
    5.Cualquier trastorno autoinmunitario, tejido conjuntivo o trastorno inflamatorio (p. ej., artritis reumatoide, síndrome de Sjögren, sarcoidosis, etc.) donde se haya documentado la existencia o sospecha de afectación pulmonar en el momento de la selección. Los detalles completos del trastorno se registrarán en el CRDe para los pacientes incluidos en el estudio.
    6.Neumonectomía previa.
    7.Presentar compresión de la médula espinal o metástasis en el sistema nervioso central clínicamente activas, definidas como no tratadas y sintomáticas, o que requieren tratamiento con corticoesteroides o antiepilépticos para controlar los síntomas asociados. Los sujetos con metástasis cerebrales clínicamente inactivas pueden ser incluidos en el estudio. Los sujetos con metástasis cerebrales tratadas que ya no son sintomáticas y que no requieren tratamiento con corticoesteroides o anticonvulsivos pueden ser incluidos en el estudio si se han recuperado del efecto tóxico agudo de la radioterapia. Deberán haber transcurrido al menos 2 semanas entre el final de la radioterapia total del cerebro y la aleatorización/el registro en el estudio.
    8.Pacientes con carcinomatosis leptomeníngea.
    9.Presentar múltiples neoplasias malignas primarias en los últimos 3 años, excepto el cáncer de piel no melanoma adecuadamente resecado, enfermedad in situ tratada de forma curativa u otros tumores sólidos tratados de forma curativa.
    10.Presentar antecedentes de reacciones graves de hipersensibilidad a los principios activos o los principios inactivos del medicamento.
    11.Presentar antecedentes de reacciones de hipersensibilidad graves a otros anticuerpos monoclonales.
    12.Tener una infección no controlada que requiere antibióticos intravenosos, antivíricos o antimicóticos.
    13.Presentar abuso de sustancias o cualquier otra afección médica, como afecciones cardíacas o psicológicas clínicamente significativas, que, en opinión del investigador, interfieran con la participación del sujeto en el estudio clínico o la evaluación de los resultados del estudio clínico.
    14.Presentar infección conocida por el virus de la inmunodeficiencia humana (VIH). A menos que lo exijan las normativas locales o el comité ético de investigación clínica (CEIC), no es necesario realizar una prueba de antígenos/anticuerpos del VIH antes de la aleatorización/inscripción.
    15.Infección activa por hepatitis B o hepatitis C, como aquellos con indicios serológicos de infección vírica en los 28 días previos a la aleatorización/al registro del estudio. Los sujetos con infección pasada o resuelta por el virus de la hepatitis B (VHB) son aptos si el antígeno de superficie de la hepatitis B (HBsAg) es negativo (-) y positivo (+) para anticuerpos contra el antígeno nuclear de la hepatitis B (anti-HBc). Los pacientes con resultado positivo para anticuerpos contra el virus de la hepatitis C (VHC) solo son aptos si la reacción en cadena de la polimerasa es negativa para ARN del VHC.
    16.Toxicidades sin resolver procedentes de tratamientos previos contra el cáncer, definidas como toxicidades (aparte de la alopecia) que aún no se han resuelto a un grado ≤1 según la versión 5.0 de los Criterios terminológicos comunes para acontecimientos adversos (Common Terminology Criteria for Adverse Events, CTCAE) del Instituto Nacional del Cáncer (National Cancer Institute, NCI) (CTCAE del NCI) o al estado inicial. Los sujetos con toxicidades crónicas de grado 2 pueden ser aptos a criterio del investigador y la aprobación del promotor.
    Ver el protocol para más información.
    E.5 End points
    E.5.1Primary end point(s)
    Confirmed objective response rate (ORR), defined as the proportion of subjects with CR or PR, assessed by BICR based on RECIST version 1.1
    La tasa de respuesta objetiva (TRO) confirmada, definida como la proporción de pacientes con RC o RP, evaluada mediante RCIE según la versión 1.1 de los RECIST.
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 weeks after the first 80 subjects are randomized for the IA and 6 months after the last subject is registered for the primary analysis
    12 semanas después de la aleatorización de los primeros 80 sujetos para el AP y 6 meses después de la inscripción del último sujeto para el análisis principal
    E.5.2Secondary end point(s)
    - Confirmed ORR;
    - Duration of response (DoR);
    - Disease control rate (DCR);
    - Clinical benefit rate (CBR);
    - Progression-free survival (PFS);
    - Overall survival (OS);
    - TEAEs (including SAEs and AESIs);
    - PROs;
    - PK profile;
    - Incidence of ADA and NAb
    -TRO confirmada
    -Duración de Respuesta (DR)
    -Tasa de control de la enfermedad( TCE)
    -Tasa beneficio clinico (TBC)
    - supervivencia sin progresión (SSP)
    -supervivencia global (SG )
    -AAST (incluidos AAGs y AAEIs)
    -RNPs
    -Perfil FC
    -Incidencia AAF y AcN
    E.5.2.1Timepoint(s) of evaluation of this end point
    Confirmed ORR, DoR, TEAEs: 12 weeks after the first 80 subjects are randomized for the IA and 6 months after the last subject is registered for the primary analysis
    DCR, PFS, DCR, CBR, OS: 12 weeks after the first 80 subjects are randomized for the IA (DCR, PFS) and 6 months after the last subject is registered for the primary analysis (DCR, CBR, PFS, OS)
    PROs, PK Profile, Incidence of ADA and NAb: 6 months after the last subject is registered or later
    TRO confirmada, DR, AAST:12 semanas después de la aleatorización de los primeros 80 sujetos para el AP y 6 meses después de la inscripción del último sujeto para el análisis principal.
    TCE, SSP,TCE,TBC,SG: 12 semanas después de la aleatorización de los primeros 80 sujetos para el AP (TCE, SSP) y 6 meses después del registro del último sujeto para el análisis principal (TCE, TBC, SSP, SG).
    -RNPs, Perfil FC, Incidencia AAF y AcN :6 meses después de la inscripción del último sujeto o más tarde
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, Biomarker Analysis, Immunogenicity, Health economics and outcomes research (HEOR), Quality of Life (QoL), Healthcare resource utilization etc.
    Tolerabilidad , Análisis de biomarcadores , Inmunogenicidad, Investigación de resultados y aspectos económicos sanitarios (Health Economics and Outcomes Research (HEOR), calidad de vida(CdV),Uso de recursos sanitarios etc.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Different dose of the same IMP
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA24
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Japan
    Korea, Republic of
    Taiwan
    United States
    Belgium
    France
    Italy
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Overall end of study will occur when the last subject last visit has occurred or the study is discontinued by the Sponsor for other reasons (administrative, program-level, or class-related).
    El fin de ensayo global ocurirá cuando la última visita del último paciente haya ocurido o cuando el ensayo es finalizado por el Promotor por otros motivos ( administrativos, a nivel del programa o relacionados con la clase).
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 45
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 75
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 43
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-05-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 19:47:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA